1	Mujer	mujer	NCFS000	C0043210#C0015780#C0086418	persona#hallazgo#estructura_corporal#organismo_vivo	0-5	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
2	de	de	SPS00	C0332285	atributo	6-8	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
3	62	62		-	-	9-11	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
4	años	año	NCMP000	C0439234	calificador	12-16	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
5	,	,	Fc	-	-	16-17	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
6	diagnosticada	diagnosticar	VMP00SF	-	-	18-31	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
7	de	de	SPS00	C0332285	atributo	32-34	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
8	hipertensión	hipertensión	NCFS000	C0020538_1	trastorno_1	35-47	406_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-	-	-	-
9	arterial	arterial	NC00SC0	C0020538_2	trastorno_2	48-56	406_QUEST_clinical_caseMIR	SENT1	B-Estructura_Corporal	-	8	3833	LOC
10	en	en	SPS00	C1720294#C0332285	calificador#atributo	57-59	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
11	tratamiento	tratamiento	NCMS000	C1273870#C0087111	procedimiento#régimen/tratamiento	60-71	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
12	con	con	SPS00	C0332287	atributo	72-75	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
13	amlodipino	amlodipino	NC00SC0	C0051696	producto#sustancia	76-86	406_QUEST_clinical_caseMIR	SENT1	B-Grp_Medicamento	-	-	-	-
14	10	10	Z	-	-	87-89	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
15	mg	mg	NCMN000	-	-	90-92	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
16	/	/	Fh	-	-	92-93	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
17	día	día	NCMS000	C0439228#C0332169	calificador	93-96	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
18	y	y	CC	C1706368	calificador	97-98	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
19	osteoporosis	osteoporosis	NCFN000	C0029456	trastorno	99-111	406_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-	-	-	-
20	establecida	establecer	VMP00SF	-	-	112-123	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
21	en	en	SPS00	C1720294#C0332285	calificador#atributo	124-126	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
22	tratamiento	tratamiento	NCMS000	C1273870#C0087111	procedimiento#régimen/tratamiento	127-138	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
23	con	con	SPS00	C0332287	atributo	139-142	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
24	denosumab	denosumab	NC00SC0	C1690432	producto#sustancia	143-152	406_QUEST_clinical_caseMIR	SENT1	B-Grp_Medicamento	-	-	-	-
25	60	60	Z	-	-	153-155	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
26	mg	mg	NCMN000	-	-	156-158	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
27	sc	sc	NC00YL0	-	-	159-161	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
28	cada	cada	DI0CS0	C1457900	calificador	162-166	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
29	6	6		-	-	167-168	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
30	meses	mes	NCMP000	C0439231	calificador	169-174	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
31	.	.	Fp	-	-	174-175	406_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-

1	Consulta	consultar	VMM02S0	C1704447_1	calificador_1	176-184	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
2	por	por	SPS00	C1704447_2	calificador_2	185-188	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
3	una	una		C0205447_1	calificador_1	189-192	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
4	clínica	clínica	NCFS000	C0442592	medio_ambiente	193-200	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
5	de	de	SPS00	C0332285	atributo	201-203	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
6	4	4		-	-	204-205	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
7	meses	mes	NCMP000	C0439231	calificador	206-211	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
8	de	de	SPS00	C0332285	atributo	212-214	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
9	evolución	evolución	NCFS000	-	-	215-224	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
10	,	,	Fc	-	-	224-225	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
11	consistente	consistente	AQ0CS0	-	-	226-237	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
12	en	en	SPS00	C1720294#C0332285	calificador#atributo	238-240	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
13	síndrome	síndrome	NCMS000	C0012634#C0039082	trastorno	241-249	406_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-	-	-	-
14	general	general	NCCS000	C0205246	calificador	250-257	406_QUEST_clinical_caseMIR	SENT2	I-Grp_Enfermedad	-	13	72	MultiE
15	,	,	Fc	-	-	257-258	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
16	fiebre	fiebre	NCFS000	C0015967	hallazgo	259-265	406_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-	-	-	-
17	de	de	SPS00	C0332285	atributo	266-268	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
18	38°C	38°C		-	-	269-273	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
19	y	y	CC	C1706368	calificador	274-275	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
20	dolor	dolor	NCMS000	C0030193	hallazgo	276-281	406_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-	-	-	-
21	continuo	continuo	AQ0MS0	C0205322#C0549178	calificador	282-290	406_QUEST_clinical_caseMIR	SENT2	B-Calificador	-	20	3834	Modif
22	en	en	SPS00	C1720294#C0332285	calificador#atributo	291-293	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
23	fosa	fosa	NCFS000	C0332471	anomalía_morfológica	294-298	406_QUEST_clinical_caseMIR	SENT2	B-Estructura_Corporal	-	20	3834	LOC
24	lumbar	lumbar	AQ0CS0	C0024090	calificador	299-305	406_QUEST_clinical_caseMIR	SENT2	I-Estructura_Corporal	-	23	106	MultiE
25	derecha	derecha	NCFS000	-	-	306-313	406_QUEST_clinical_caseMIR	SENT2	I-Estructura_Corporal	-	23	106	MultiE
26	.	.	Fp	-	-	313-314	406_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-

1	La	el	DA0FS0	-	-	315-317	406_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
2	exploración	exploración	NCFS000	C1280903	procedimiento	318-329	406_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
3	muestra	mostrar	VMIP3S0	-	-	330-337	406_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
4	una	una		C0205447_1	calificador_1	338-341	406_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
5	puñopercusión	puñopercusión	NCFS000	-	-	342-355	406_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
6	renal	renal	AQ0CS0	-	-	356-361	406_QUEST_clinical_caseMIR	SENT3	B-Estructura_Corporal	-	-	-	-
7	positiva	positivo	AQ0FS0	C1446409	calificador	362-370	406_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
8	.	.	Fp	-	-	370-371	406_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-

1	Se	se	P00CN000	-	-	372-374	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
2	solicita	solicitar	VMIP3S0	-	-	375-383	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
3	una	una		C0205447_1	calificador_1	384-387	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
4	analítica	analítica	NCFS000	-	-	388-397	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
5	que	que	PR0CN000	-	-	398-401	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
6	muestra	mostrar	VMIP3S0	-	-	402-409	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
7	leucocitos	leucocito	NCMP000	C0023516	célula	410-420	406_QUEST_clinical_caseMIR	SENT4	B-Estructura_Corporal	-	-	-	-
8	14.000/mm3	14.000/mm3		-	-	421-431	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
9	sin	sin	SPS00	C0332288	atributo	432-435	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
10	desviación	desviación	NCFS000	C0185033#C0333051	procedimiento#anomalía_morfológica	436-446	406_QUEST_clinical_caseMIR	SENT4	B-Grp_Enfermedad	Negacion	-	-	-
11	izquierda	izquierdo	AQ0FS0	C0205091	calificador	447-456	406_QUEST_clinical_caseMIR	SENT4	B-Calificador	-	10	3836	Modif
12	,	,	Fc	-	-	456-457	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
13	con	con	SPS00	C0332287	atributo	458-461	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
14	Hb	hb	NC00YL0	-	-	462-464	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
15	9	9	Z	-	-	465-466	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
16	g	g	NCMN000	-	-	467-468	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
17	/	/	Fh	-	-	468-469	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
18	dL	decilitro	NCMN000	C0439241	calificador	469-471	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
19	y	y	CC	C1706368	calificador	472-473	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
20	una	una		C0205447_1	calificador_1	474-477	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
21	VSG	velocidad_de_sedimentación_globular	NC00YL0	-	-	478-481	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
22	de	de	SPS00	C0332285	atributo	482-484	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
23	82	82	Z	-	-	485-487	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
24	mm	mm	NCMN000	-	-	488-490	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
25	a	a	SPS00	-	-	491-492	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
26	la	el	DA0FS0	-	-	493-495	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
27	primera	1	AO0FS0	-	-	496-503	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
28	hora	hora	NCFS000	C0040223#C0439227	calificador	504-508	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
29	.	.	Fp	-	-	508-509	406_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-

1	El	el	DA0MS0	-	-	510-512	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
2	sedimento	sedimento	NCMS000	C2945609#C1261248_1	hallazgo#sustancia_1	513-522	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
3	urinario	urinario	NCMS000	C2945609#C1261248_2	hallazgo#sustancia_2	523-531	406_QUEST_clinical_caseMIR	SENT5	B-Estructura_Corporal	-	-	-	-
4	presenta	presentar	VMIP3S0	-	-	532-540	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
5	leucocituria	leucocituria	NCFS000	-	-	541-553	406_QUEST_clinical_caseMIR	SENT5	B-Grp_Enfermedad	-	-	-	-
6	y	y	CC	C1706368	calificador	554-555	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
7	la	el	DA0FS0	-	-	556-558	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
8	citología	citología	NCFS000	-	-	559-568	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
9	de	de	SPS00	C0332285	atributo	569-571	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
10	la	el	DA0FS0	-	-	572-574	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
11	orina	orina	NCFS000	C0042036	sustancia	575-580	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
12	muestra	mostrar	VMIP3S0	-	-	581-588	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
13	abundantes	abundante	AQ0CP0	-	-	589-599	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
14	macrófagos	macrófago	NCMP000	C0024432	célula	600-610	406_QUEST_clinical_caseMIR	SENT5	B-Grp_Enfermedad	-	-	-	-
15	con	con	SPS00	C0332287	atributo	611-614	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
16	aspecto	aspecto	NCMS000	C0700364#C0233426#C0332441	calificador#función	615-622	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
17	espumoso	espumoso	AQ0MS0	-	-	623-631	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-
18	.	.	Fp	-	-	631-632	406_QUEST_clinical_caseMIR	SENT5	-	-	-	-	-

